Khadra Helmi, Kholmatov Roostam, Monlezun Dominique, Kandil Emad
Division of Endocrine and Oncologic Surgery, Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Cytopathology. 2018 Dec;29(6):565-568. doi: 10.1111/cyt.12608. Epub 2018 Aug 3.
A feared complication of thyroid fine needle aspiration (FNA) is bleeding diathesis and haematoma at the biopsy site. Patients are often advised to discontinue antithrombotic/anticoagulant (AT/AC) medications prior to the procedure. The aim of this study was to examine the risk of bleeding in patients on AT/AC medications undergoing cervical ultrasound (US)-guided FNA.
A retrospective chart review of 803 patients who underwent US-guided FNA of thyroid nodules over 8 years by a single endocrine surgeon was undertaken. Clinical variables, patient demographics and use of AT/AC medications were collected and analysed. The principle outcome measures included the incidence of procedure-related haematoma formation. Multivariable logistic regression was used to investigate the possible independent association between post-FNA haematoma and anticoagulation, adjusting for age, African American race, body mass index, vascularity and lesion size.
A total of 1568 lesions were included in 803 patients. The mean age for the patients on AT/AC was 63.0 ± 10.4 years and those not on AT/AC was 50.1 ± 14.2 years (P < 0.001). Of those, 148 patients had 336 lesions (21%) biopsied while taking one or more daily AT/AC agent (81 patients: aspirin; 11 patients: Plavix; 17 patients: aspirin and warfarin; 30 patients: aspirin and Plavix; seven patients: rivaroxaban and aspirin; and two patients: ticagrelor and aspirin). Three patients (0.89%) in the AT/AC group compared to six patients (0.49%) not receiving AT/AC medications developed a haematoma (P = 0.41). All complications were treated conservatively and none required intervention.
US-guided FNA of thyroid lesions can be safely performed on patients taking AT/AC including newer agents, without an increase in adverse outcomes or decreased diagnostic rate. Further larger prospective multi-institutional studies are warranted to further investigate this important finding.
甲状腺细针穿刺活检(FNA)令人担忧的并发症是活检部位的出血素质和血肿形成。通常建议患者在手术前停用抗血栓/抗凝(AT/AC)药物。本研究的目的是检查接受颈部超声(US)引导下FNA的服用AT/AC药物患者的出血风险。
对一位内分泌外科医生在8年期间对803例接受甲状腺结节US引导下FNA的患者进行回顾性病历审查。收集并分析临床变量、患者人口统计学资料和AT/AC药物的使用情况。主要结局指标包括与手术相关的血肿形成发生率。采用多变量逻辑回归分析FNA术后血肿与抗凝之间可能的独立关联,并对年龄、非裔美国人种族、体重指数、血管情况和病变大小进行校正。
803例患者共纳入1568个病变。服用AT/AC药物患者的平均年龄为63.0±10.4岁,未服用AT/AC药物患者的平均年龄为50.1±14.2岁(P<0.001)。其中,148例患者在服用一种或多种每日AT/AC药物时对336个病变(21%)进行了活检(81例患者:阿司匹林;11例患者:氯吡格雷;17例患者:阿司匹林和华法林;30例患者:阿司匹林和氯吡格雷;7例患者:利伐沙班和阿司匹林;2例患者:替格瑞洛和阿司匹林)。AT/AC组有3例患者(0.89%)发生血肿,未接受AT/AC药物治疗组有6例患者(0.49%)发生血肿(P=0.41)。所有并发症均采用保守治疗,无一例需要干预。
对于服用包括新型药物在内的AT/AC药物的患者,可安全地进行US引导下的甲状腺病变FNA,不会增加不良后果或降低诊断率。有必要进行进一步更大规模的前瞻性多机构研究以进一步探究这一重要发现。